SCHEMBL6886531

SCHEMBL6886531

O=C[C@H](O)[C@@H](O)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16807902 1.00
SCHEMBL13413381 1.00
SCHEMBL8265625 1.00
SCHEMBL18726946 1.00
SCHEMBL2560705 1.00
SCHEMBL9273942 0.97 TSHR (0.50)
SCHEMBL11037568 0.82 TSHR (0.47)
SCHEMBL14038079 0.82 TSHR (0.47)
SCHEMBL29623845 0.82 TSHR (0.47)
SCHEMBL29624067 0.82 TSHR (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170151153-A1 POWERFUL HAIR TREATMENT AGENT WITH ANTI-WASHOUT EFFECT HENKEL AG & CO. KGAA (DE) 2017-06-01 US disclosed
WO-2016128996-A2 AN IMPROVED PROCESS FOR PREPARATION OF TICAGRELOR AND INTERMEDIATES THEREOF STRIDES SHASUN LIMITED (IN) 2016-08-18 WO disclosed
US-8546404-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME (US) 2013-10-01 US disclosed
EP-1794126-B1 CRYSTALLINE FORM OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE HEMI-TARTRATE ACADIA PHARM INC (US) 2013-03-20 EP disclosed
US-8288531-B2 Preparation process BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-16 US disclosed
WO-2011110954-A1 HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY ACTAVIS GROUP PTC EHF (IS) 2011-09-15 WO disclosed
WO-2010023561-A9 PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF ACTAVIS GROUP PTC EHF (IS) 2011-08-04 WO disclosed
US-20110087021-A1 NOVEL PREPARATION PROCESS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-04-14 US disclosed
WO-2010151476-A2 CRYSTALLINE FORMS OF (3R, 3AS, 6AR) - HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R) - (1-{4-[ (DIETHOXYPHOSPHORYL) METHOXY] PHENY1}-3-HYDROXY-4- [4-METHOXY-N- (2-METHYLPROPYL) BENZENESUL - FONAMIDO] BUTAN-2-YL) CARBAMATE GILEAD SCIENCES, INC. (US) 2010-12-29 WO disclosed
WO-2010143070-A2 AMORPHOUS VARENICLINE TARTRATE CO-PRECIPITATES ACTAVIS GROUP PTC EHF (IS) 2010-12-16 WO disclosed
WO-2009143347-A9 VARENICLINE TOSYLATE, AN INTERMEDIATE IN THE PREPARATION PROCESS OF VARENICLINE L-TARTRATE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2010-07-29 WO disclosed
EP-1735302-B1 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS LILLY CO ELI (US) 2010-06-16 EP disclosed
WO-2010023561-A1 PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF ACTAVIS GROUP PTC EHF (IS) 2010-03-04 WO disclosed
WO-2010005643-A1 PROCESSES FOR PURIFYING VARENICLINE L-TARTRATE SALT AND PREPARING CRYSTALLINE FORMS OF VARENICLINE L-TARTRATE SALT TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2010-01-14 WO disclosed
WO-2009143347-A2 VARENICLINE TOSYLATE, AN INTERMEDIATE IN THE PREPARATION PROCESS OF VARENICLINE L-TARTRATE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-11-26 WO disclosed
US-7556844-B2 Radiation curable photochromic inks XEROX CORPORATION (US) 2009-07-07 US disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 US disclosed
US-7459014-B2 Radiation curable inks containing curable gelator additives XEROX CORPORATION (US) 2008-12-02 US disclosed
US-20070211110-A1 RADIATION CURABLE PHOTOCHROMIC INKS XEROX CORPORATION (US) 2007-09-13 US disclosed
WO-2007088073-A1 ZOPICLONE RESOLUTION USING L-TARTARIC ACID SYNTHON B.V. (NL) 2007-08-09 WO disclosed